T0	Limitation 15905 15906	A
T1	Limitation 16075 16082	Because
T2	Limitation 16271 16278	Delayed
T3	Limitation 16431 16434	For
T4	Limitation 16595 16607	Furthermore,
T5	Limitation 16681 16683	We
T6	Limitation 16812 16814	We
T7	Limitation 17068 17070	An
T8	Limitation 17235 17237	We
T9	Limitation 18071 18073	In
T10	InappropriateFollowUpDuration 15987 16073	did not call patients back for study visits for detailed assessment of quality of life
T11	ResponsivenessOfMeasurement 16220 16269	chose poor outcome as our primary outcome measure
T12	OutcomeMeasures 16362 16429	did not include delayed cerebral haemorrhage as a secondary outcome
T13	OutcomeMeasures 16455 16498	did not include other baseline measurements
#1	AnnotatorNotes T13	No appropriate outcome measuring method
#2	AnnotatorNotes T12	No appropriate outcome measuring method
T14	OTHER 16611 16679	do not have complete information about adherence to study medication
T15	OTHER 16684 16747	did not require magnesium concentration to be routinely checked
#3	AnnotatorNotes T15	In appropriate study implementation
T16	Blinding 16834 16875	possibility of unmasking of investigators
#4	AnnotatorNotes T16	Blinding Investigator
T17	LackOfOutcomeMeasurementData 17071 17233	effect of magnesium treatment on cognitive symptoms—which are common after aneurysmal subarachnoid haemorrhage—might have been missed by the modified Rankin Scale
T18	OTHER 18088 18163	time to treatment with magnesium in MASH 2 might not have been short enough
#5	AnnotatorNotes T18	Not adequate treatment time
T19	InappropriateFollowUpDuration 17371 17404	a benefit might be detected later
